<DOC>
	<DOCNO>NCT01624701</DOCNO>
	<brief_summary>This pilot clinical trial ass feasibility efficacy expand umbilical cord blood derive blood stem cell transplantation use combination chemical factor stromal co-culture . Bone marrow ( BM ) mesenchymal stromal cell ( MSC ) obtain separate bone marrow donor . One cord blood unit expand method another cord blood unit infuse without manipulation . The expanded cord blood unit help boost initial recovery blood count transplantation , though expect unexpanded cord blood unit provide cell lead long term engraftment blood stem cell . A third cord blood unit identify standby cord blood unit expansion fail .</brief_summary>
	<brief_title>Clinical Ex Vivo Expansion Human Umbilical Cord Blood Stem Progenitor Cells</brief_title>
	<detailed_description>1 . Clinical transplantation two cord blood unit : one ex vivo expand another unmanipulated unit function back-up . 2 . Ten patient select : - Allogeneic haematopoietic stem cell transplant indicate ( see detail ) - No matched sibling match unrelated donor available quickly enough transplant ( fully match donor find within 1 month initiation donor search donor find available donation within 3 month donor search ) . - At least three unrelated donor cord blood unit identify less 2 antigen mismatch patient insufficient cell dose meet patient 's requirement . If clinical efficacy protocol demonstrate , proceed multicentre clinical trial patient . 3 . The investigator obtain haplo-identical MSC bone marrow sibling/parent/offspring patient . Although MSC co-infused cord blood cell , show safe trial MSC give patient graft versus host disease ( GVHD ) human leukocyte antigen ( HLA ) match MSC recipient show important . bone marrow mesenchymal stroma cell ( BM-MSCs ) derive related donor bone marrow minimum 2/6 HLA match safe use patients.1 If haplo-identical MSC donor available , match unrelated donor MSC would also use . 4 . Efficacy assess follow compare publish literature well historical control : - Neutrophil platelet engraftment - Post transplant 100-day mortality - Overall progression-free survival If clinical efficacy protocol demonstrate , investigator proceed multicentre clinical trial patient .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<criteria>Patients Department Haematology , Singapore General Hospital , diagnose list meet inclusion criterion . They deem suitable trial respective attending doctor well panel least three hematologist . Suitability reassess Principal Investigator 1 . Patients age 12 year 60 year . 2 . Patient currently available HLAA , B , C , DRB1 DQB1 match related unrelated donor . 3 . Patient must hematologic malignancy require allogeneic haematopoietic stem cell transplantation define ( National Marrow Donor Program American Society Blood Marrow Transplantation Guidelines ) agree upon panel least three hematologist specialize transplantation . Acute myelogenous leukemia ( AML ) : Highrisk AML include : Antecedent hematological disease ( e.g. , myelodysplasia ( MDS ) ) Treatmentrelated leukemia Induction failure 1st complete remission ( CR1 ) poorrisk cytogenetics molecular marker ( e.g . Flt 3 mutation , 11q23 etc ) 2nd complete remission ( CR2 ) beyond Acute lymphoblastic leukemia ( ALL ) CR1 age 35 Highrisk age 35 include : Poorrisk cytogenetics ( e.g. , Philadelphia chromosome ( 9 ; 22 ) 11q23 rearrangement ) High white cell count ( &gt; 30,000/mm3 ) diagnosis CNS testicular leukemia No CR within 4 week initial treatment Induction failure CR2 beyond Myelodysplastic syndrome ( MDS ) Intermediate1 ( INT1 ) , intermediate2 ( INT2 ) high IPSS score include : &gt; 5 % marrow blast Other good risk cytogenetics ( 5q normal ) &gt; 1 lineage cytopenia Chronic myelogenous leukemia ( CML ) Disease progression Accelerated phase Blast crisis ( myeloid lymphoid ) Follicular lymphoma Poor response initial treatment After second subsequent relapse Transformation diffuse large Bcell lymphoma Aggressive Tcell BCell lymphoma After second subsequent relapse No CR initial treatment Mantle Cell : After second subsequent relapse Hodgkin 's lymphoma No initial CR After second subsequent relapse Multiple myeloma : Patients fail autologous transplantation chromosome 13 abnormality , first response last less 6 month , Î²2 microglobulin &gt; 3 mg/L may consider protocol initial therapy . 1 . Inadequate Organ Function define : Renal : Creatinine clearance &gt; 60ml/min Hepatic : Bilirubin , AST/ALT &lt; 2x upper limit normal Pulmonary function : DLCOcorr &gt; 50 % normal Cardiac : leave ventricular ejection fraction &gt; 45 % 2 . Karnofsky score ( adult ) &lt; 70 % Lansky score &lt; 50 % ( pediatrics )</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Cord blood</keyword>
	<keyword>unrelated donor</keyword>
	<keyword>allogeneic</keyword>
	<keyword>cell dose</keyword>
</DOC>